Tanshinone 11A used in preparing medicine for preventing and treating atherosclerosis
A technology of atherosclerosis and tanshinone, applied in the field of tanshinone 11A for the preparation of drugs for the prevention and treatment of atherosclerosis
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0021] Dried Salvia miltiorrhiza 1kg, extracted with 95% ethanol for 3 times, each time for 24 hours, the extract was concentrated under reduced pressure to 500mL, then added 500mL of water, extracted four times with 1000mL chloroform, the extract was concentrated under reduced pressure, and the column layer Analysis and separation, the silica gel is 100-200 mesh, the eluent is petroleum ether / ethyl acetate mixed solution containing 1%-10% ethyl acetate, and gradient elution is carried out. About 0.85g of tanshinone IIA can be obtained. Embodiment 2: Tanshinone IIA reduces the experiment of hyperlipidemia animal model (rat) arterial vessel wall intima cholesterol deposition experiment
Embodiment 2
[0022] The experimental animals were 48 adult male rats (Sprague-Dawley) with a body weight of 150-200 g. Divided into normal control group, hyperlipidemia model control group, positive drug cholestyramine (500mg / kg) control group, tanshinone IIA high dose (300mg / kg), medium dose (100mg / kg), low dose (30mg / kg) G. Except for the normal control group, the other groups were fed with high cholesterol and lipid feed for 45 consecutive days.
[0023] High cholesterol and lipid feed formula: 3% cholesterol, 10% lard, 0.2% methylthiouracil and 88% basic feed.
[0024] Determination of cholesterol content in arterial wall: isopropanol extraction, high iron-acetic acid-sulfuric acid chromogenic method. The experimental results are shown in Table 1.
[0025] The reduction rate calculation method in Table 1 and the following tables: reduction rate=[1-(treatment group concentration-normal control group concentration) / hyperlipidemia model control group concentration-normal control group ...
Embodiment 3
[0028] The experimental animals were 48 adult male rats (Sprague-Dawley) with a body weight of 150-200 g. Divided into normal control group, hyperlipidemia model control group, positive drug cholestyramine (500mg / kg) control group, tanshinone IIA high dose (300mg / kg), medium dose (100mg / kg), low dose (30mg / kg) G. Except for the normal control group, the other groups were fed with high cholesterol and lipid feed for 45 consecutive days.
[0029] High cholesterol and lipid feed formula: 3% cholesterol, 10% lard, 0.2% methylthiouracil and 88% basic feed.
[0030] Determination method of serum cholesterol content: ferric-acetic acid-sulfuric acid chromogenic method. The experimental results are shown in Table 2.
[0031] The results of this experiment show that tanshinone IIA basically does not affect the metabolism of cholesterol. It shows that tanshinone IIA reduces the cholesterol deposition in the arterial intima through a new mechanism of action, that is, the competition ...
PUM
Property | Measurement | Unit |
---|---|---|
weight | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com